Results 221 to 230 of about 170,256 (261)

Advances in Spatial Heterogeneity and Cellular Localization Specificity of Intratumoral Bacteria

Cancer Science, EarlyView.
Spatial localization of intratumoral bacteria governs their functional roles in tumor progression, metastasis, and treatment responses, with guiding significance for clinical management, as reviewed across three spatial paradigms. ABSTRACT Bacteria in tumors are increasingly recognized to be a part of the tumor microenvironment and their biological ...
Minlan Ren, Jing Jia, Tingting Li, Yiwei Li, Nanxiang Shen, Yun Shi, Zhe Wang, Hao Fan, Guangli Sun, Guanying Xiong, Gang Li, Rui Peng   +11 more
wiley   +1 more source

Enfortumab Vedotin plus Pembrolizumab as First-line Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Results from EV-202 Cohort 9. [PDF]

Clin Cancer Res
Swiecicki PL, Hanna GJ, Geiger JL, Fujisawa T, Haigentz M, Honma Y, Bruce JY, Tanaka K, Muro K, Bhateja P, Kaplan J, Liu S, Gorla S, Wozniak M, Dillon R, Hamed S, Meng C, Chaney MF, Rosenberg AJ.   +18 more
europepmc   +1 more source

Comprehensive Genomic Profiling Beyond Driver Testing in Non‐Squamous Non‐Small Cell Lung Cancer With Known Drivers

Cancer Science, EarlyView.
Figure 6 Comprehensive genomic profiling identified additional actionable alterations in a substantial proportion of patients with non‐squamous NSCLC despite previously identified driver alterations, with some findings leading to subsequent matched targeted therapies.
Yoshihiro Masui, Tatsuya Yoshida, Yoh Yamaguchi, Jun Miyakoshi, Ryoko Inaba Higashiyama, Akiko Tateishi, Yuki Shinno, Yuji Matsumoto, Yusuke Okuma, Tomonori Mizutani, Hidehito Horinouchi, Kouya Shiraishi, Takashi Kohno, Takafumi Koyama, Noboru Yamamoto, Yasushi Goto   +15 more
wiley   +1 more source

Pembrolizumab-Induced Morphea in a Patient With Metastatic Urothelial Carcinoma. [PDF]

Case Rep Urol
Drescher MA, Murray DW, Grider DJ.
europepmc   +1 more source

Incidence, severity and potential pathomechanism of immune‐related pruritus in melanoma patients undergoing immune checkpoint inhibitor therapy

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and objectives Pruritus is a frequent cutaneous immune‐related adverse event (irAE) associated with immune checkpoint inhibitors (ICI), impacting patients' quality of life. This study investigates the incidence, severity and management of pruritus in melanoma patients treated with ICI.
Andrea Roggo, Nikolina Ivanovic, Patrick Turko, Lukas Kraehenbuehl, Mitchell Levesque, Reinhard Dummer, Barbara Meier‐Schiesser   +6 more
wiley   +1 more source

A Phase II Trial of Pembrolizumab plus Granulocyte-Macrophage Colony-Stimulating Factor in Advanced Biliary Cancer. [PDF]

Clin Cancer Res
Kelley RK, Bracci P, Gordan JD, Behr SC, Quandt Z, Atreya CE, Kidder WA, Ko AH, Lim HC, Van Loon K, Adeniji N, Venook AP, Fong L, Keenan BP.   +13 more
europepmc   +1 more source

Significant Intracranial Response and Long-term Survival after Pembrolizumab in Non-small Cell Lung Cancer Brain Metastases Resistant to Stereotactic Radiotherapy. [PDF]

NMC Case Rep J
Noda R, Akabane A, Kawashima M, Segawa M, Shimoi A, Masuda Y, Morikawa T, Usui K, Inoue T.   +8 more
europepmc   +1 more source